Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24289267 | 0.74 | ALDH1A1 (0.37) | F12 | |
| SCHEMBL21836693 | 0.73 | MTOR (0.31) | F12 | |
| SCHEMBL24289263 | 0.73 | TNKS2 (0.35) | F12 | |
| SCHEMBL21836666 | 0.70 | UGCG (0.44) | — | |
| SCHEMBL6709142 | 0.69 | HTR2A (0.37) | F12HTR2AHTR2CHTR2B | |
| SCHEMBL21836668 | 0.68 | SLC22A12 (0.35) | F12HTR2AHTR2B | |
| SCHEMBL22344795 | 0.65 | UGCG (0.40) | — | |
| SCHEMBL16920673 | 0.63 | POLB (0.35) | F12 | |
| SCHEMBL24289261 | 0.61 | UGCG (0.41) | — | |
| SCHEMBL14621344 | 0.61 | POLB (0.36) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597725-B2 | URAT1 inhibitor for promoting uric acid excretion | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-03-07 | — | — | US | disclosed |
| CN-108484600-B | URAT1 inhibitors for promoting uric acid excretion | 江苏新元素医药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-3632904-B1 | URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| EP-3632904-B1 | URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20200262832-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| EP-3632904-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597725-B2 | URAT1 inhibitor for promoting uric acid excretion | SLC10A6, SLC10A1, SLC28A1 | F12 3078/4885HTR2A 2578/4885HTR2C 3511/4885 |
| US-20200262832-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | SLC10A6, SLC10A1, SLC28A1 | F12 3078/4885HTR2A 2578/4885HTR2C 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.